Technically correct; however, BMY's clear intention on its ASCO webcast was to convey that they're including a broader group of first-line NSCLC patients than a 50% cut-off based on MRK's assay.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”